Apogee Therapeutics, Inc.
APGE
Classement en actions
#2337
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prix de l'action
$135.07
Dernière synchronisation: 2026-09-04
Capitalisation boursière
$8.36B
Changement (1 jour)
0.00%
Changement (1 an)
152.56%
Pays
US
Échange Apogee Therapeutics, Inc. (APGE)
Catégorie
Healthcare
Historique du prix de l'action pour Apogee Therapeutics, Inc. (APGE)
Prix de clôture le plus élevé : $135.07 le 2026-09-01
Prix de clôture le plus bas : $20.79 le 2023-07-01
Prix de clôture le plus bas : $20.79 le 2023-07-01
Historique du prix de l'action de Apogee Therapeutics, Inc. de 2023 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $523.31 | 22.71% |
US
|
|
| $237.47 | 784.43% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $874.99 | 7.47% |
NL
|
|
| $287.83 | 1.13% |
BE
|
